1932

Abstract

The genomic era has been characterized by an exponential increase in the number of targets in the management of breast cancer. Prognostic profiling has helped to determine which tumors are more likely to be associated with poor disease-free survival. Gene expression profiles are being studied in order to improve predictions of response and toxicity. Epigenetics is being evaluated for its ability to influence estrogen receptor expression. However, these fields require further validation. This review discusses the advances in the management of breast cancer through genomic evaluation.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.med.60.061107.145152
2009-02-18
2024-06-22
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.med.60.061107.145152
Loading
/content/journals/10.1146/annurev.med.60.061107.145152
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error